About Us
Investors
Amunix is profitable and has $13M in cash. As a consequence, Amunix has not needed to accept investments from venture capital companies or any other outsiders.
To finance clinical development of Amunix’ XTEN products, Amunix has spun off a company called Versartis Inc. (www.versartis.com), which has the rights to develop three specific XTEN products for metabolic disease, that were created by Amunix. Amunix owns 50% of Versartis and the other 50% is owned by Index Ventures (Geneva, Switzerland), a leading European venture capital firm (www.indexventures.com) which has provided the financing for the clinical development.
 |
 |
 |